Skip to main navigation
logo
  • Home
  • Overview
  • News & Events
    • Press Releases
    • Events and Presentations
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Financials
    • SEC Filings
    • Annual Reports
    • Quarterly Releases
  • Governance
    • Governance Overview
    • Board of Directors
    • Management
    • Committee Composition
  • IR Resources
    • Email Alerts
    • Contact IR

Press Releases

Press Releases

February 22, 2022
Athira Pharma to Present Preclinical Data at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
February 22, 2022
Athira Pharma Announces Publication of Phase 1 Results for Fosgonimeton (ATH-1017) in The Journal of Alzheimer's Disease
January 31, 2022
Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors
January 25, 2022
Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
January 5, 2022
Athira Pharma Provides 2022 Pipeline Outlook
November 10, 2021
Athira Pharma Reports Third Quarter 2021 Financial Results and Business Update
November 10, 2021
Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer’s Disease at CTAD Conference
November 8, 2021
Athira Pharma to Present at Upcoming Investor Conferences
October 29, 2021
Athira Pharma to Host Educational Webinar on the Clinical Applications of ERP P300
October 22, 2021
Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Current page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page next ›
  • Last page last »
Displaying 41 - 50 of 93
< SIGN UP FOR EMAIL ALERTS
CONTACT IR

Athira Pharma, Inc.
18706 North Creek Parkway
Suite 104
Bothell, WA 98011

Main line: (866) 725-0930
Local number: (425) 620-8501
info@athira.com

FCOI Policy

Privacy Policy

© Athira Pharma, Inc. All rights reserved.